Inhibitors of cyclin-dependent kinase 7 (CDK7)
The present invention provides novel compounds of Formula (I) and Formula (II) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, melanoma, multiple myeloma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of cyclin-dependent kinase 7 (CDK7), and therefore, induce cellular apoptosis and/or inhibit transcription in the subject.
1. A pharmaceutical composition comprising a compound of the formula
or a stereoisomer thereof, and a pharmaceutically acceptable excipient.
2. A pharmaceutical composition comprising a pharmaceutically acceptable salt of a compound of the formula
or a stereoisomer thereof, and a pharmaceutically acceptable excipient.
3. The pharmaceutical composition of claim 2 , wherein the pharmaceutically acceptable salt is a hydrochloric acid salt.
4. The pharmaceutical composition of claim 1 , wherein the composition is an aqueous solution.
5. The pharmaceutical composition of claim 1 , wherein the composition is formulated for parenteral administration.
6. The pharmaceutical composition of claim 5 , wherein the composition is formulated for intravenous or intralesional injection or infusion.
7. The pharmaceutical composition of claim 1 , wherein the composition is in a single unit dosage form or packaged as a plurality of single unit dosages.
8. The pharmaceutical composition of claim 2 , wherein the composition is an aqueous solution.
9. The pharmaceutical composition of claim 2 , wherein the composition is formulated for parenteral administration.
10. The pharmaceutical composition of claim 9 , wherein the composition is formulated for intravenous or intralesional injection or infusion.
11. The pharmaceutical composition of claim 2 , wherein the composition is in a single unit dosage form or packaged as a plurality of single unit dosages.
12. The pharmaceutical composition of claim 3 , wherein the composition is an aqueous solution.
13. The pharmaceutical composition of claim 3 , wherein the composition is formulated for parenteral administration.
14. The pharmaceutical composition of claim 13 , wherein the composition is formulated for intravenous or intralesional injection or infusion.
15. The pharmaceutical composition of claim 3 , wherein the composition is in a single unit dosage form or packaged as a plurality of single unit dosages.
16. The pharmaceutical composition of claim 1 , wherein the composition comprises the stereoisomer of the compound.
17. The pharmaceutical composition of claim 2 , wherein the composition comprises the stereoisomer of the salt of the compound.
18. The pharmaceutical composition of claim 3 , wherein the composition comprises the stereoisomer of the salt of the compound.